Ativo Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Ativo Capital Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-368,380	Closed	-$5.61M	–	52
2024 Q2	$5.61M	Buy	368,380 +15	+0%	+$215	5.81%	3
2024 Q1	$5.4M	Sell	368,365 -63,285	-15%	-$924K	5.42%	3
2023 Q4	$6.01M	Sell	431,650 -34,500	-7%	-$461K	6.42%	2
2023 Q3	$6.23M	Sell	466,150 -6,500	-1%	-$87.9K	7.04%	2
2023 Q2	$5.97M	Buy	+472,650	New	+$5.52M	6.3%	2
2021 Q1	–	Sell	-262,995	Closed	-$3.75M	–	132
2020 Q4	$3.75M	Sell	262,995 -103,285	-28%	-$1.39M	1.61%	10
2020 Q3	$5.1M	Buy	+366,280	New	+$4.37M	2.45%	7
2015 Q4	–	Sell	-200,185	Closed	-$2.12M	–	199
2015 Q3	$2.12M	Sell	200,185 -60,150	-23%	-$747K	0.56%	47
2015 Q2	$3.46M	Buy	260,335 +79,740	+44%	+$880K	1.22%	16
2015 Q1	$2.06M	Buy	180,595 +11,070	+7%	+$117K	0.81%	37
2014 Q4	$1.71M	Sell	169,525 -163,945	-49%	-$1.73M	0.7%	49
2014 Q3	$3.5M	Buy	333,470 +114,710	+52%	+$1.08M	1.38%	15
2014 Q2	$1.89M	Buy	+218,760	New	+$1.84M	0.82%	45

Other funds holding RDY

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ativo Capital Management's RDY Position: Q3 2024 in Review

Ativo Capital Management sold out of Dr. Reddy's Laboratories (RDY) in Q3 2024, closing a stake of 368,380 shares — an estimated $5.61M sold.

Ativo Capital Management first reported a position in RDY in Q2 2014 and held it in 13 quarters. The position peaked at $6.23M in Q3 2023. 227 funds tracked by Wall St. Rank hold RDY as of Q3 2024.

Ativo Capital Management reported no remaining Dr. Reddy's Laboratories position as of Q3 2024 after selling out during the quarter.
Ativo Capital Management sold 368,380 Dr. Reddy's Laboratories shares in Q3 2024, an estimated $5.61M.
Ativo Capital Management first reported a position in Dr. Reddy's Laboratories in Q2 2014 and held it in 13 quarters.
Ativo Capital Management's Dr. Reddy's Laboratories position peaked at $6.23M in Q3 2023.
227 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2024.

Based on Ativo Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.